Source: International Congress 2019 – Treatment of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
J. Lee (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), B. Chang (Seoul, Republic of Korea), C. Choi (Seoul, Republic of Korea), Y. Kim (Seoul, Republic of Korea), H. Choi (Seoul, Republic of Korea), W. Kwak (Seoul, Republic of Korea), M. Park (Seoul, Republic of Korea), W. Jeon (Seoul, Republic of Korea). Positive PD-L1 expression is associated with unfavorable clinical outcome in EGFR-mutated lung adenocarcinomas treated with EGFR-TKIs. 367

Member's Comments

No comment yet.

Related content which might interest you: Survival prognosis and target therapy best response in adenocarcinoma lung cancer pts with mutation EGFR gene Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 The positive prognostic impact of Bcl-xl and Bcl-2 in chemo-naive lung cancer patients depends on stage and histology Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018 p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer Source: Annual Congress 2007 - Novel genetic markers in pathology Year: 2007 Tumor specific MUC1 expression in operable lung cancer correlates with improved survival Source: Eur Respir J 2005; 26: Suppl. 49, 459s Year: 2005 PD-L1 is a potential negative prognostic factor for non-small cell lung cancer: A 5-year-follow-up study Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011 Clinical relevance of p53 and K-ras gene mutations in bronchial margins in surgically treated nonsmall cell lung cancer (NSCLC) patients Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002 Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 596s Year: 2002 The expression of Bcl-xl correlates with improved survival in chemo-naive, surgically resected NSCLC patients Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology Year: 2007 ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009 Efficacy of osimertinib and histomolecular profile at progression in EGFR-mutated lung cancer Source: International Congress 2019 – Treatment of lung cancer Year: 2019 The association of p53 and p21 expression with clinicopathological parameters and prognosis in non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Analysis of clinical factors in relationship to treatment effects of erlotinib in non small cell lung cancer (NSCLC) patients Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Fascin-1 overexpression predicts a poor prognosis in non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Efficacy and prognostic factors of first-line afatinib treatment for the EGFR-mutated non-small cell lung cancer in the real world Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Survival outcomes of patients diagnosed with lung adenocarcinoma with ALK gene rearrangement Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 The prognostic value of the expression of GST-π in response to chemotherapy in cytological and pathological specimens of patients with lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002 TTF-1 for prediction of response to chemotherapy in patients with locally advanced or metastatic small cell lung cancer (SCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001